About Faraday Pharmaceuticals

Faraday Pharmaceuticals is developing FDY-5301, a therapeutic that utilizes sodium iodide to neutralize hydrogen peroxide during ischemia-reperfusion injury, thereby reducing cardiac damage and inflammation. This approach aims to mitigate the adverse effects of myocardial infarctions and decrease the risk of heart failure in patients undergoing percutaneous coronary intervention.

```xml <problem> Myocardial infarctions lead to ischemia-reperfusion injury (IRI), causing cardiac damage and increasing the risk of heart failure. Current treatments often fail to fully address the hydrogen peroxide produced during IRI, resulting in continued tissue damage and inflammation. </problem> <solution> Faraday Pharmaceuticals is developing FDY-5301, an investigational therapeutic that utilizes sodium iodide to neutralize hydrogen peroxide produced during ischemia-reperfusion injury. By targeting IRI, FDY-5301 aims to reduce cardiac damage, inflammation, and infarct size in patients experiencing myocardial infarctions. The product is intended to complement percutaneous coronary intervention (PCI) in the management of ST-elevation myocardial infarction (STEMI). </solution> <features> - Utilizes sodium iodide to neutralize hydrogen peroxide. - Designed to reduce tissue damage, inflammation, and infarct size. - Easy-to-administer formulation. - Currently in Phase 3 clinical trials (Iocyte AMI-3) to assess its potential to reduce heart failure and cardiovascular death among patients suffering from an anterior STEMI. </features> <target_audience> The primary target audience includes patients experiencing myocardial infarctions, specifically those undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). </target_audience> ```

What does Faraday Pharmaceuticals do?

Where is Faraday Pharmaceuticals located?

Faraday Pharmaceuticals is based in Seattle, United States.

When was Faraday Pharmaceuticals founded?

Faraday Pharmaceuticals was founded in 2014.

Location

Seattle, United States

Founded

2014

Employees

26 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Faraday Pharmaceuticals

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

faradaypharma.com 2K+

Founded 2014 – Seattle, United States

Funding

No funding information available.

Team (25+)

No team information available.

Company Description

Problem

Myocardial infarctions lead to ischemia-reperfusion injury (IRI), causing cardiac damage and increasing the risk of heart failure. Current treatments often fail to fully address the hydrogen peroxide produced during IRI, resulting in continued tissue damage and inflammation.

Solution

Faraday Pharmaceuticals is developing FDY-5301, an investigational therapeutic that utilizes sodium iodide to neutralize hydrogen peroxide produced during ischemia-reperfusion injury. By targeting IRI, FDY-5301 aims to reduce cardiac damage, inflammation, and infarct size in patients experiencing myocardial infarctions. The product is intended to complement percutaneous coronary intervention (PCI) in the management of ST-elevation myocardial infarction (STEMI).

Features

Utilizes sodium iodide to neutralize hydrogen peroxide.

Designed to reduce tissue damage, inflammation, and infarct size.

Easy-to-administer formulation.

Currently in Phase 3 clinical trials (Iocyte AMI-3) to assess its potential to reduce heart failure and cardiovascular death among patients suffering from an anterior STEMI.

Target Audience

The primary target audience includes patients experiencing myocardial infarctions, specifically those undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).